ClinicalTrials.gg
RecruitingNCT04003363Updated Oct 6, 2026

The United Kingdom National Registry for Myotonic Dystrophy

An observational study in Myotonic Dystrophy, sponsored by Newcastle University. Recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Newcastle University · Observational

How we know

From the registry’s dates

  • Started May 2013; still recruiting 13 years 6 months later.
Updated Oct 6, 2026Study contact changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
900
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Myotonic Dystrophy with a site in United Kingdom — 12 open to participants now, 14 under way, 5 of them phase 3. Myotonic Dystrophy · United Kingdom.

Started
2013
the only one that year
Observational
5 of 22
2 open now
Primary completion
2030-01
later than 12 of 13 live
Registered
6th of 22
by date
Lead sponsor
1 of 22
Newcastle University

Among the 22 studies in Myotonic Dystrophy with a site in United Kingdom, this one is the only one that started in 2013, is one of 5 observational ones, reaches primary completion later than 12 of the 13 other live ones, and was the 6th registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

12 of the 22 studies in Myotonic Dystrophy with a site in United Kingdom are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Myotonic Dystrophy with a site in United Kingdom, or all of them as a file.
02

Study summary

Myotonic dystrophy (dystrophia myotonica - DM) exists in two forms, usually referred to as DM1 (type 1) and DM2 (type 2). Both conditions are genetic disorders but each affects a different gene. DM1 is the most common adult-onset muscular dystrophy, and is thought to affect at least 1 in 8,000 people worldwide.

The aim is to facilitate a questionnaire based research study in order to better characterise and understand the disease in the UK. By maintaining a national registry this will help identify potential participants eligible for clinical trials in the future.

Read the detailed description

The UK DM Patient Registry (https://www.dm-registry.org/uk/) aims to recruit any individual, from anywhere within the United Kingdom, with a diagnosis of myotonic dystrophy. Participants may be referred to the registry by health care professionals, or genetic testing/laboratory centres who are aware of the registry. Alternatively, a participant may have discovered the registry via promotional activities or by their own online searches. After completing the consent process, participants are able to enter information on to the registry platform (note all forms are also available offline as well). This is an ongoing database and all participants will invited to update their information on an annual basis.

The registry is sponsored by Muscular Dystrophy UK, Cure-DM and the Myotonic Dystrophy Support Group.

The database is divided into two main sections:

  1. Mandatory items (demographic information, clinical diagnosis, genetic test result, current best motor function and wheelchair use) and
  2. Highly encouraged items (severity of muscle symptoms, cardiac status, respiratory function, digestion, cataracts, and fatigue, ethnic origin and data on involvement with other registries)

The database is designed to be self reporting, however where specialised clinical or genetic information is required, the neuromuscular specialist in charge of the participants care can be invited to provide some additional information. The participant is able to select a health care provider from a pre-populated list at registration stage, if they wish to (optional feature). This information is included in the patient information and consent.

03

Conditions studied

  • Myotonic Dystrophy

Browse trials for

Keywords

  • Myotonic Dystrophy
  • Myotonic Dystrophy Type 1
  • Myotonic Dystrophy Type 2
  • DM
  • DM1
  • DM2
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with Myotonic Dystrophy will volunteer to participate in this study. The study will be advertised through neuromuscular disease clinics, the registry website, patient organisations and conferences and meetings throughout the UK.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients with a confirmed Myotonic Dystrophy diagnosis (or pending diagnosis) are eligible for inclusion. Diagnosis will be confirmed via genetic testing results

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria for the registry
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
900 participants (estimated)
Target follow-up
20 Years
Patient registry
Yes

Groups and cohorts

  • Participants with Myotonic Dystrophy

    Other: Patient Registry

Interventions

  • OtherPatient Registry

    Participants who have volunteered to participate will complete various questionnaires relating to their condition.

06

What researchers measure

Primary outcomes

  1. Patient questionnaire

    Patient reported myotonic dystrophy clinical diagnosis, symptoms relating to muscle weakness, motor function, medication use, family history and ethnicity.

    Time frame: 12 months

  2. Clinician questionnaire

    Clinician reported patient cardiac measures, medication use, respiratory measures and genetic confirmation of myotonic dystrophy.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • John Walton Muscular Dystrophy Research Centre
    Newcastle upon Tyne, NE1 3BZ, United Kingdom
    Recruiting
08

References and documents

Publications

  • Wood L, Cordts I, Atalaia A, Marini-Bettolo C, Maddison P, Phillips M, Roberts M, Rogers M, Hammans S, Straub V, Petty R, Orrell R, Monckton DG, Nikolenko N, Jimenez-Moreno AC, Thompson R, Hilton-Jones D, Turner C, Lochmuller H. The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research. J Neurol. 2017 May;264(5):979-988. doi: 10.1007/s00415-017-8483-2. Epub 2017 Apr 10. PubMed 28397002 ↗
  • Best AF, Hilbert JE, Wood L, Martens WB, Nikolenko N, Marini-Bettolo C, Lochmuller H, Rosenberg PS, Moxley RT 3rd, Greene MH, Gadalla SM. Survival patterns and cancer determinants in families with myotonic dystrophy type 1. Eur J Neurol. 2019 Jan;26(1):58-65. doi: 10.1111/ene.13763. Epub 2018 Sep 16. PubMed 30051542 ↗
  • Alsaggaf R, Wang Y, Marini-Bettolo C, Wood L, Nikolenko N, Lochmuller H, Greene MH, Gadalla SM. Benign and malignant tumors in the UK myotonic dystrophy patient registry. Muscle Nerve. 2018 Feb;57(2):316-320. doi: 10.1002/mus.25736. Epub 2017 Jul 24. PubMed 28662292 ↗
  • Wood L, Bassez G, Bleyenheuft C, Campbell C, Cossette L, Jimenez-Moreno AC, Dai Y, Dawkins H, Manera JAD, Dogan C, El Sherif R, Fossati B, Graham C, Hilbert J, Kastreva K, Kimura E, Korngut L, Kostera-Pruszczyk A, Lindberg C, Lindvall B, Luebbe E, Lusakowska A, Mazanec R, Meola G, Orlando L, Takahashi MP, Peric S, Puymirat J, Rakocevic-Stojanovic V, Rodrigues M, Roxburgh R, Schoser B, Segovia S, Shatillo A, Thiele S, Tournev I, van Engelen B, Vohanka S, Lochmuller H. Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease. Orphanet J Rare Dis. 2018 Sep 5;13(1):155. doi: 10.1186/s13023-018-0889-0. PubMed 30185236 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2013 (actual). Primary completion is estimated for Jan 2030, 200 months after the start.

Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 200 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2019
First posted
Jul 1, 2019
StartActual
May 2013
Primary completionEst.
Jan 2030
CompletionEst.
Dec 2030
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • John Walton Muscular Dystrophy Research Centre · Newcastle upon Tyne, United Kingdom
Show 1 removed
  • John Walton Muscular Dystrophy Research Centre · Newcastle Upon Tyne, United Kingdom
Oct 6, 2026
Contact
Study contact changed: h•••@newcastle.ac.uk · •••8640→r•••@ncl.ac.uk · •••8640; removed r•••@ncl.ac.uk. See the current contact
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    1 site added, 1 site removed
    Show site
    • John Walton Muscular Dystrophy Research Centre · Newcastle upon Tyne, United Kingdom
    Show 1 removed
    • John Walton Muscular Dystrophy Research Centre · Newcastle Upon Tyne, United Kingdom
    Contact Study contact changed: h•••@newcastle.ac.uk · •••8640→r•••@ncl.ac.uk · •••8640; removed r•••@ncl.ac.uk. See the current contact
    + 3 other changes: verification date, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04003363
Lead sponsor
Newcastle University
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
May 2013
Primary completion
Jan 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 6, 2026

Study contacts

Registry Curator
Contact
registries@ncl.ac.uk
0191 2418640
Chiara Marini-Bettolo, MD, PhD
principal investigator · John Walton Muscular Dystrophy Research Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion